Research

Health·Medicine·News-EN·Personalized Medicine·Research

Groundbreaking Cancer Study: Nivolumab Delivers Remarkable Results for Endometrial Cancer Patients

Nivolumab, an immunotherapy drug, shows an 80% complete response rate in phase 2 trials for resectable dMMR/MSI-H endometrial cancer. The trial results, announced at the 2025 SGO Annual Meeting, suggest reduced need for surgery among patients with total tumor remission. One patient

March 16, 2025

Health·Medicine·News-EN·Research·xIT·xPL

The Liver’s Awakening: A New Breakthrough in Fighting Pancreatic Cancer Spread

The liver, traditionally a sanctuary for cancer metastasis, faces a new defensive strategy against pancreatic cancer spread. UCLA researchers have developed a nanotechnology solution, using mRNA vaccine-armed nanoparticles, to galvanize the liver’s immune response. The nanoparticles, constructed from lipid-like materials, target the

March 12, 2025